GlassScriptPhysician profile
Robert T Garbacz
NPI 1134107360
$4,267.01
in general payments reported to CMS, 2019-2025
21 companies · $422 in 2025
The $422 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $460 · 2021: $712 · 2022: $684 · 2023: $596 · 2024: $938 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.46 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $945.83 | 2020-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $478.12 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $451.95 | 2020-2025 | Ilumya |
| Janssen Biotech, INC. | $406.64 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Biofrontera INC. | $352.12 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Novartis Pharmaceuticals Corporation | $314.81 | 2020-2025 | |
| Abbvie INC. | $309.29 | 2019-2025 | |
| Pfizer INC. | $248.76 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $150.07 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $145.15 | 2019-2023 | |
| Galderma Laboratories, L.P. | $110.83 | 2019-2025 | Nemluvio, Aklief |
| Incyte Corporation | $62.30 | 2021-2024 | Opzelura |
| Verrica Pharmaceuticals INC. | $54.19 | 2023-2024 | Ycanth |
| Dermavant Sciences, INC. | $53.75 | 2023-2024 | Vtama |
| Paratek Pharmaceuticals, INC. | $41.66 | 2023 | Nuzyra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.56 | 2023 | Otezla |
| Merck Sharp & Dohme LLC | $24.94 | 2019 | |
| Almirall LLC | $22.68 | 2022 | |
| Dusa Pharmaceuticals, INC. | $21.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.25 | 2023 | Libtayo |
| Revance Therapeutics, INC. | $18.72 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Garbacz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.